Dr. David W. Dougherty
Overview
David Dougherty is an Oncologist in Philadelphia, Pennsylvania. Dr. Dougherty is highly rated in 9 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Large-Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma. Dr. Dougherty is currently accepting new patients.
His clinical research consists of co-authoring 18 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.
Graduate Institution
Residency
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE MAPD
- MEDICARE MAPD
- OTHER MEDICARE
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- EPO
- POS
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- MEDICARE SNP
- EPO
- HMO
- POS
- PPO
- EPO
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, Philadelphia, PA 19104
Additional Areas of Focus
Dr. Dougherty has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Abramson Cancer Center Perelman 2nd Floor West
Corey Langer is an Oncologist in Philadelphia, Pennsylvania. Dr. Langer is highly rated in 14 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Langer is currently accepting new patients.
University Of Pennsylvania
Jakub Svoboda is an Oncologist in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 27 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.
Abramson Cancer Center Perelman 2nd Floor West
Charu Aggarwal is an Oncologist in Philadelphia, Pennsylvania. Dr. Aggarwal is highly rated in 18 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Aggarwal is currently accepting new patients.
Frequently Asked Questions about Dr. David W. Dougherty
How do I make an appointment with Dr. David W. Dougherty?
You can book an appointment with Dr. David W. Dougherty by calling their office at 215-615-5858. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. David W. Dougherty a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. David W. Dougherty is classified as an Advanced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. David W. Dougherty specialize in?
While Dr. David W. Dougherty is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Large-Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.
Does Dr. David W. Dougherty participate in research or clinical trials?
Yes. Dr. David W. Dougherty has published 18 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. David W. Dougherty's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. David W. Dougherty accept my insurance?
Dr. David W. Dougherty accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 215-615-5858 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- ALK-Positive Non-Small Cell Lung CancerDr. Dougherty isAdvanced. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- EGFR Positive Lung CancerDr. Dougherty isAdvanced. Learn about EGFR Positive Lung Cancer.
- Large-Cell Lung CarcinomaDr. Dougherty isAdvanced. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Dougherty isAdvanced. Learn about Lung Adenocarcinoma.
- Lung CancerDr. Dougherty isAdvanced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)Dr. Dougherty isAdvanced. Learn about Non-Small Cell Lung Cancer (NSCLC).
- Experienced
- MesotheliomaDr. Dougherty isExperienced. Learn about Mesothelioma.
- Metastatic Pleural TumorDr. Dougherty isExperienced. Learn about Metastatic Pleural Tumor.
- Thymic Epithelial TumorDr. Dougherty isExperienced. Learn about Thymic Epithelial Tumor.